サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1781300

特発性血小板減少性紫斑病治療薬の世界市場

Idiopathic Thrombocytopenic Purpura Therapeutics

出版日
ページ情報
英文 277 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.26円
特発性血小板減少性紫斑病治療薬の世界市場
出版日: 2025年08月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 277 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

特発性血小板減少性紫斑病治療薬の世界市場は2030年までに8億4,750万米ドルに達する見込み

2024年に6億6,590万米ドルと推定される特発性血小板減少性紫斑病治療薬の世界市場は、2030年には8億4,750万米ドルに達し、分析期間2024～2030年のCAGRは4.1%で成長すると予測されます。本レポートで分析したセグメントの1つである急性免疫性血小板減少性紫斑病は、CAGR 4.6%を記録し、分析期間終了時には5億2,540万米ドルに達すると予測されます。慢性疾患セグメントの成長率は、分析期間中CAGR 3.5%と推定されます。

米国市場は1億8,140万米ドルと推定、中国はCAGR7.6％で成長予測

米国の特発性血小板減少性紫斑病治療薬市場は、2024年には1億8,140万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに1億7,360万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは7.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.6%と3.2%と予測されています。欧州では、ドイツがCAGR 2.4%で成長すると予測されています。

特発性血小板減少性紫斑病（ITP）治療薬の治療戦略における最新の進歩とは？

特発性血小板減少性紫斑病（ITP）治療薬の世界市場- 主要動向と促進要因のまとめ

特発性血小板減少性紫斑病（ITP）治療薬の世界市場は、疾患の有病率の増加と治療法の進歩に牽引され、着実な成長を遂げています。ITPは血小板数の減少を特徴とする自己免疫疾患であり、出血やあざの原因となります。同市場には、副腎皮質ステロイド、免疫グロブリン静注（IVIG）、抗D免疫グロブリン、トロンボポエチン受容体作動薬（TPO-RA）、患者の予後改善を目的とした新たな治療法など、さまざまな治療選択肢があります。

ITPの治療戦略は進化しており、ガイドラインでは出血リスク、血小板数、これまでの治療に対する反応性に基づいて、患者個々に対応した治療が重視されています。

どのような革新がITP治療法の展望を変えつつあるのか？

ITP治療薬の状況は、有効性と患者のQOLを高めることを目的とした重要な技術革新に直面しています。新たな治療法は、脾チロシンキナーゼ（SYK）阻害薬や新生児Fc受容体（FcRn）拮抗薬など、血小板破壊に関与する免疫経路を調節する新たな作用機序に焦点を当てています。これらの進歩は、難治性ITP患者や既存の治療に不耐容の患者に対する代替療法となる可能性があります。

さらに、バイオマーカーを利用して治療反応を予測し、それに応じて治療を調整する個別化医療のアプローチも検討されています。この個別化戦略は、治療成績を最適化し、副作用を最小限に抑えることを目的としています。さらに、バイオシミラーや既存薬の改良型製剤の開発により、治療へのアクセスや患者のアドヒアランスが向上しています。

ITP治療薬市場の成長はいくつかの要因によってもたらされる

ITP治療薬市場の拡大は、以下のようないくつかの重要な要因によって推進されています。

  • 治療選択肢の進歩：新規治療薬や標的薬剤の導入により、治療選択肢の幅が広がり、さまざまな重症度や治療歴を持つ患者に対応できるようになりました。
  • 病気の認識と診断の向上：医療従事者と患者における認知度の向上は、早期診断と早期介入につながり、患者の転帰を改善し、治療適格者を拡大した。
  • 高齢化：世界人口の高齢化に伴い、高齢者におけるITPの有病率が高いことから、ITPの発症率は上昇すると予想され、効果的な治療薬に対する需要が高まっています。
  • 戦略的提携と研究イニシアティブ：製薬企業、研究機関、患者支援団体の協力により、革新的な治療法の開発と臨床試験が促進され、新しい治療法の市場開発が加速しています。

これらの要因が相まって、ITP治療薬市場はダイナミックな成長と進化を遂げており、アンメットメディカルニーズへの対応とITP患者のQOL向上を目指しています。

セグメント

疾患（急性免疫性血小板減少性紫斑病、慢性疾患、その他の疾患）、製品（副腎皮質ステロイド、IVIG、抗D免疫グロブリン、TPO-RA、その他）

調査対象企業の例

  • Amgen Inc.
  • argenx SE
  • eXIthera Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd
  • Grifols, S.A.
  • GSK plc.
  • Harbour BioMed
  • HUTCHMED
  • InnoCare Pharma Limited
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Keros Therapeutics, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Principia Biopharma（acquired by Sanofi）
  • Qilu Pharmaceutical Co., Ltd.
  • Rigel Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • UCB S.A.
  • Veralox Therapeutics, Inc.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革します。

Global Industry Analystsは、一般的なLLMや業界別SLMにクエリーする代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP31529

Global Idiopathic Thrombocytopenic Purpura Therapeutics Market to Reach US$847.5 Million by 2030

The global market for Idiopathic Thrombocytopenic Purpura Therapeutics estimated at US$665.9 Million in the year 2024, is expected to reach US$847.5 Million by 2030, growing at a CAGR of 4.1% over the analysis period 2024-2030. Acute Immune Thrombocytopenic Purpura Disease, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$525.4 Million by the end of the analysis period. Growth in the Chronic Disease segment is estimated at 3.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$181.4 Million While China is Forecast to Grow at 7.6% CAGR

The Idiopathic Thrombocytopenic Purpura Therapeutics market in the U.S. is estimated at US$181.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$173.6 Million by the year 2030 trailing a CAGR of 7.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 3.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.4% CAGR.

Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics: What Are the Latest Advances in Treatment Strategies?

Global ITP Therapeutics Market - Key Trends & Drivers Summarized

The global market for Idiopathic Thrombocytopenic Purpura (ITP) therapeutics is experiencing steady growth, driven by an increasing prevalence of the disorder and advancements in treatment modalities. ITP is an autoimmune condition characterized by a low platelet count, leading to bleeding and bruising. The market encompasses various therapeutic options, including corticosteroids, intravenous immunoglobulins (IVIG), anti-D immunoglobulins, thrombopoietin receptor agonists (TPO-RAs), and emerging treatments aimed at improving patient outcomes.

Treatment strategies for ITP have evolved, with guidelines emphasizing individualized patient care based on bleeding risk, platelet count, and response to previous therapies.

Which Innovations Are Transforming the ITP Therapeutics Landscape?

The ITP therapeutics landscape is witnessing significant innovations aimed at enhancing efficacy and patient quality of life. Emerging therapies are focusing on novel mechanisms of action, such as spleen tyrosine kinase (SYK) inhibitors and neonatal Fc receptor (FcRn) antagonists, which modulate immune pathways involved in platelet destruction. These advancements offer potential alternatives for patients with refractory ITP or those intolerant to existing treatments.?

Additionally, personalized medicine approaches are being explored, utilizing biomarkers to predict treatment responses and tailor therapies accordingly. This individualized strategy aims to optimize outcomes and minimize adverse effects. Furthermore, the development of biosimilars and improved formulations of existing drugs is enhancing accessibility and patient adherence to treatment regimens.?

The Growth in the ITP Therapeutics Market Is Driven by Several Factors…

The expansion of the ITP therapeutics market is propelled by several key factors:?

  • Advancements in Treatment Options: The introduction of novel therapies and targeted agents has broadened the spectrum of treatment choices, catering to patients with varying disease severities and treatment histories.?
  • Increased Disease Awareness and Diagnosis: Enhanced awareness among healthcare professionals and patients has led to earlier diagnosis and intervention, improving patient outcomes and expanding the treatment-eligible population.?
  • Aging Population: As the global population ages, the incidence of ITP is expected to rise, given its higher prevalence among older individuals, thereby driving demand for effective therapeutics.
  • Strategic Collaborations and Research Initiatives: Collaborations between pharmaceutical companies, research institutions, and patient advocacy groups are fostering the development of innovative treatments and facilitating clinical trials, accelerating the introduction of new therapies to the market.?

Collectively, these factors are contributing to the dynamic growth and evolution of the ITP therapeutics market, aiming to address unmet medical needs and enhance the quality of life for patients with ITP.?

SCOPE OF STUDY:

The report analyzes the Idiopathic Thrombocytopenic Purpura Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease (Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease, Other Diseases); Product (Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics, Other Idiopathic Thrombocytopenic Purpura Therapeutic Products)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • Amgen Inc.
  • argenx SE
  • eXIthera Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd
  • Grifols, S.A.
  • GSK plc.
  • Harbour BioMed
  • HUTCHMED
  • InnoCare Pharma Limited
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Keros Therapeutics, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Principia Biopharma (acquired by Sanofi)
  • Qilu Pharmaceutical Co., Ltd.
  • Rigel Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • UCB S.A.
  • Veralox Therapeutics, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Idiopathic Thrombocytopenic Purpura Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Disease Awareness and Early Diagnosis Propel Demand for ITP Therapies
    • Increased Use of Thrombopoietin Receptor Agonists Drives Growth in Second-Line Treatments
    • Development of Novel Targeted Biologics Expands Therapeutic Options for Chronic ITP
    • Growing Pediatric and Geriatric Patient Pools Create Demand for Tailored Treatment Regimens
    • Advances in Autoimmune Disease Understanding Strengthen Business Case for Precision Therapies
    • Increasing Clinical Trial Activity Spurs Innovation in Next-Gen ITP Therapeutics
    • Growing Use of Combination Therapies Enhances Treatment Outcomes and Market Differentiation
    • Regulatory Fast Track and Orphan Drug Designations Accelerate Product Launch Timelines
    • Physician Education and Updated Treatment Guidelines Drive Adoption of New Drug Classes
    • Improved Diagnostic Accuracy and Biomarker Research Throws Spotlight on Personalized ITP Treatment
    • Expansion of Hospital-Based Infusion Services Facilitates Uptake of Intravenous Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Idiopathic Thrombocytopenic Purpura Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Acute Immune Thrombocytopenic Purpura Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Acute Immune Thrombocytopenic Purpura Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Acute Immune Thrombocytopenic Purpura Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Chronic Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Chronic Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Chronic Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for IVIG Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for IVIG Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for IVIG Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Idiopathic Thrombocytopenic Purpura Therapeutic Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Idiopathic Thrombocytopenic Purpura Therapeutic Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other Idiopathic Thrombocytopenic Purpura Therapeutic Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Idiopathic Thrombocytopenic Purpura Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • JAPAN
    • Idiopathic Thrombocytopenic Purpura Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • CHINA
    • Idiopathic Thrombocytopenic Purpura Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • EUROPE
    • Idiopathic Thrombocytopenic Purpura Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • FRANCE
    • Idiopathic Thrombocytopenic Purpura Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • GERMANY
    • Idiopathic Thrombocytopenic Purpura Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Idiopathic Thrombocytopenic Purpura Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Idiopathic Thrombocytopenic Purpura Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Idiopathic Thrombocytopenic Purpura Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • INDIA
    • Idiopathic Thrombocytopenic Purpura Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Idiopathic Thrombocytopenic Purpura Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Idiopathic Thrombocytopenic Purpura Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • AFRICA
    • Idiopathic Thrombocytopenic Purpura Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030

IV. COMPETITION